Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• B-cell maturation antigen (BCMA) is a promising target in multiple myeloma due to its overexpression on cancer cells.
• Chimeric antigen receptor (CAR) T-cell therapy has shown success, but antibody-based therapeutics offer alternative strategies.

Purpose of the Study:

• To design and evaluate novel bispecific BCMA-CD3 antibodies for multiple myeloma treatment.
• To assess the binding, cytotoxic activity, and in vivo efficacy of these engineered antibodies.

Main Methods:

• Development of various univalent and bivalent bispecific BCMA-CD3 antibody formats (CrossMAB, ScFv-Fc).
• Assessment of antibody binding to BCMA-positive cells and T cells using FACS.
• Evaluation of cytotoxic activity and IFN-gamma secretion in vitro.
• Testing in vivo efficacy using a multiple myeloma xenograft mouse model.

Main Results:

• All developed BCMA-CD3 antibodies exhibited specific binding to target cells and T cells with nanomolar affinity.
• Antibodies demonstrated potent, dose-dependent killing of multiple myeloma cells in vitro.
• Significant IFN-gamma secretion was observed, indicating T-cell activation.
• Three bispecific antibodies showed high efficacy in an in vivo multiple myeloma xenograft model.

Conclusions:

• Novel humanized BCMA-CD3 bispecific antibodies are highly effective against multiple myeloma.
• These antibodies represent a promising therapeutic strategy for further preclinical and clinical development.